Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016, Article ID 4626125, 13 pages
http://dx.doi.org/10.1155/2016/4626125
Review Article

Urinary Biomarkers in the Assessment of Early Diabetic Nephropathy

1Division of Nephrology, University of Medicine and Pharmacy “V. Babes”, 300041 Timisoara, Romania
2Romanian Academy of Medical Sciences, 300041 Timisoara, Romania
3Department of Diabetes and Metabolic Diseases, University of Medicine and Pharmacy “V. Babes”, 300041 Timisoara, Romania
4Division of Hematology, University of Medicine and Pharmacy “V. Babes”, 300041 Timisoara, Romania
5Department of Biochemistry, University of Medicine and Pharmacy “V. Babes”, 300041 Timisoara, Romania

Received 24 March 2016; Accepted 12 May 2016

Academic Editor: Nikolaos Papanas

Copyright © 2016 Cristina Gluhovschi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. J. Macisaac, E. I. Ekinci, and G. Jerums, “Markers of and risk factors for the development and progression of diabetic kidney disease,” American Journal of Kidney Diseases, vol. 63, no. 2, pp. S39–S62, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Narres, H. Claessen, S. Droste et al., “The incidence of end-stage renal disease in the diabetic (compared to the non-diabetic) population: a systematic review,” PLoS ONE, vol. 11, no. 1, Article ID e0147329, 2016. View at Publisher · View at Google Scholar
  3. E. Lioudaki, K. G. Stylianou, I. Petrakis et al., “Increased urinary excretion of podocyte markers in normoalbuminuric patients with diabetes,” Nephron, vol. 131, no. 1, pp. 34–42, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Banu, H. Hara, M. Okamura, G. Egusa, and M. Yamakido, “Urinary excretion of type IV collagen and laminin in the evaluation of nephropathy in NIDDM: comparison with urinary albumin and markers of tubular dysfunction and/or damage,” Diabetes Research and Clinical Practice, vol. 29, no. 1, pp. 57–67, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Kubisz, L. Stanciaková, J. Staško, P. Galajda, and M. Mokáň, “Endothelial and platelet markers in diabetes mellitus type 2,” World Journal of Diabetes, vol. 6, no. 3, pp. 423–431, 2015. View at Publisher · View at Google Scholar
  6. G. Tramonti and Y. S. Kanwar, “Tubular biomarkers to assess progression of diabetic nephropathy,” Kidney International, vol. 79, no. 10, pp. 1042–1044, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Terami, J. Wada, K. Inoue et al., “Urinary angiotensinogen is a marker for tubular injuries in patients with type 2 diabetes,” International Journal of Nephrology and Renovascular Disease, vol. 6, pp. 233–240, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Eriguchi, R. Yotsueda, K. Torisu et al., “Assessment of urinary angiotensinogen as a marker of podocyte injury in proteinuric nephropathies,” American Journal of Physiology—Renal Physiology, vol. 310, no. 4, pp. F322–F333, 2016. View at Publisher · View at Google Scholar
  9. A. Matheson, M. D. P. Willcox, J. Flanagan, and B. J. Walsh, “Urinary biomarkers involved in type 2 diabetes: a review,” Diabetes/Metabolism Research and Reviews, vol. 26, no. 3, pp. 150–171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Y. Hong and K. S. Chia, “Markers of diabetic nephropathy,” Journal of Diabetes and Its Complications, vol. 12, no. 1, pp. 43–60, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. J. H. Warram, L. J. Scott, L. S. Hanna et al., “Progression of microalbuminuria to proteinuria in type 1 diabetes: nonlinear relationship with hyperglycemia,” Diabetes, vol. 49, no. 1, pp. 94–100, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Fioretto, M. W. Steffes, and M. Mauer, “Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria,” Diabetes, vol. 43, no. 11, pp. 1358–1364, 1994. View at Publisher · View at Google Scholar · View at Scopus
  13. K. McKenna and C. Thompson, “Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus,” Scottish Medical Journal, vol. 42, no. 4, pp. 99–104, 1997. View at Google Scholar · View at Scopus
  14. P. Hovind, L. Tarnow, P. Rossing et al., “Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study,” British Medical Journal, vol. 328, no. 7448, pp. 1105–1108, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. I. H. de Boer, T. C. Rue, P. A. Cleary et al., “Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort,” Archives of Internal Medicine, vol. 171, no. 5, pp. 412–420, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Zoppini, G. Targher, M. Chonchol et al., “Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 3, pp. 401–408, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. B. A. Perkins, L. H. Ficociello, B. E. Ostrander et al., “Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes,” Journal of the American Society of Nephrology, vol. 18, no. 4, pp. 1353–1361, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. D. J. Newman, M. B. Mattock, A. B. Dawnay et al., “Systematic review on urine albumin testing for early detection of diabetic complications,” Health Technology Assessment, vol. 9, no. 30, 2005. View at Google Scholar
  19. H.-H. Parving, J. B. Lewis, M. Ravid, G. Remuzzi, and L. G. Hunsicker, “Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective,” Kidney International, vol. 69, no. 11, pp. 2057–2063, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Lu, J. Wen, X. Y. Song et al., “High prevalence of albuminuria in population-based patients diagnosed with type 2 diabetes in the Shanghai downtown,” Diabetes Research and Clinical Practice, vol. 75, no. 2, pp. 184–192, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Ismail, B. Becker, P. Strzelczyk, and E. Ritz, “Renal disease and hypertension in non-insulin-dependent diabetes mellitus,” Kidney International, vol. 55, no. 1, pp. 1–28, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. S.-I. Araki, M. Haneda, D. Koya et al., “Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes,” Diabetes, vol. 56, no. 6, pp. 1727–1730, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. R. G. Nelson, P. H. Bennett, G. J. Beck et al., “Development and progression of renal disease in Pima Indians with non- insulin-dependent diabetes mellitus,” The New England Journal of Medicine, vol. 335, no. 22, pp. 1636–1642, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. S. C. W. Tang, J. C. K. Leung, and K. N. Lai, “Diabetic tubulopathy: an emerging entity,” in Diabetes and the Kidney, K. N. Lai and S. C. W. Tang, Eds., Karger, 2011. View at Google Scholar
  25. K. Kunika, T. Yamaoka, and M. Itakura, “Damage of charge-dependent renal tubular reabsorption causes diabetic microproteinuria,” Diabetes Research and Clinical Practice, vol. 36, no. 1, pp. 1–9, 1997. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Currie, G. Mc Kay, and C. Delles, “Biomarkers in diabetic nephropathy: present and future,” World Journal of Diabetes, vol. 5, no. 6, pp. 763–776, 2014. View at Publisher · View at Google Scholar
  27. T. Narita, H. Sasaki, M. Hosoba et al., “Parallel increase in urinary excretion rates of immunoglobulin G, ceruloplasmin, transferrin, and orosomucoid in normoalbuminuric type 2 diabetic patients,” Diabetes Care, vol. 27, no. 5, pp. 1176–1181, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Kanauchi, Y. Akai, and T. Hashimoto, “Transferrinuria in type 2 diabetic patients with early nephropathy and tubulointerstitial injury,” European Journal of Internal Medicine, vol. 13, no. 3, pp. 190–193, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Quiroga, D. Arroyo, and G. de Arriba, “Present and future in the treatment of diabetic kidney disease,” Journal of Diabetes Research, vol. 2015, Article ID 801348, 13 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Kazumi, T. Hozumi, Y. Ishida et al., “Increased urinary transferrin excretion predicts microalbuminuria in patients with type 2 diabetes,” Diabetes Care, vol. 22, no. 7, pp. 1176–1180, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Cohen-Bucay and G. Viswanathan, “Urinary markers of glomerular injury in diabetic nephropathy,” International Journal of Nephrology, vol. 2012, Article ID 146987, 11 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Wang, C. Li, W. Gong, and T. Lou, “New urinary biomarkers for diabetic kidney disease,” Biomarker Research, vol. 1, article 9, 2013. View at Publisher · View at Google Scholar
  33. M. Yamazaki, S. Ito, A. Usami et al., “Urinary excretion rate of ceruloplasmin in non-insulin-dependent diabetic patients with different stages of nephropathy,” European Journal of Endocrinology, vol. 132, no. 6, pp. 681–687, 1995. View at Publisher · View at Google Scholar · View at Scopus
  34. L. X. Qin, X. Zeng, and G. Huang, “Changes in serum and urine ceruloplasmin concentrations in type 2 diabetes,” Zhong Nan Da Xue Xue Bao Yi Xue Ban, vol. 29, no. 2, pp. 208–211, 2004. View at Google Scholar
  35. J. T. Tamsma, J. van den Born, J. A. Bruijn et al., “Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane,” Diabetologia, vol. 37, no. 3, pp. 313–320, 1994. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Fiseha, “Urinary biomarkers for early diabetic nephropathy in type 2 diabetic patients,” Biomarker Research, vol. 3, article 16, 2015. View at Publisher · View at Google Scholar
  37. N. Kotajima, T. Kimura, T. Kanda et al., “Type IV collagen as an early marker for diabetic nephropathy in non-insulin-dependent diabetes mellitus,” Journal of Diabetes and its Complications, vol. 14, no. 1, pp. 13–17, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Takizawa, T. Satoh, A. Kurusu et al., “Increase of urinary type IV collagen in normoalbuminuric patients with impaired glucose tolerance,” Nephron, vol. 79, no. 4, pp. 474–475, 1998. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Okonogi, M. Nishimura, Y. Utsunomiya et al., “Urinary type IV collagen excretion reflects renal morphological alterations and type IV collagen expression in patients with type 2 diabetes mellitus,” Clinical Nephrology, vol. 55, no. 5, pp. 357–364, 2001. View at Google Scholar · View at Scopus
  40. S. Ming, Z. Qi, L. Wang, and K. Zhu, “Urinary type IV collagen: a specific indicator of incipient diabetic nephropathy,” Chinese Medical Journal, vol. 115, no. 3, pp. 389–394, 2002. View at Google Scholar · View at Scopus
  41. S. Kado, A. Aoki, S. Wada et al., “Urinary type IV collagen as a marker for early diabetic nephropathy,” Diabetes Research and Clinical Practice, vol. 31, no. 1–3, pp. 103–108, 1996. View at Publisher · View at Google Scholar · View at Scopus
  42. I. Ueta, K. Takamatsu, and K. Hashimoto, “Urinary glycosaminoglycans in patients with incipient diabetic nephropathy,” Nihon Jinzo Gakkai Shi, vol. 37, no. 1, pp. 17–23, 1995. View at Google Scholar · View at Scopus
  43. O. Torffvit, “Urinary sulphated glycosaminoglycans and Tamm-Horsfall protein in type 1 diabetic patients,” Scandinavian Journal of Urology and Nephrology, vol. 33, no. 5, pp. 328–332, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. Uehara, H. Makino, K. Seiki, and Y. Urade, “Urinary excretions of lipocalin-type prostaglandin D synthase predict renal injury in type-2 diabetes: a cross-sectional and prospective multicentre study,” Nephrology Dialysis Transplantation, vol. 24, no. 2, pp. 475–482, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Kuboki, H. Tada, K. Shin, Y. Oshima, and S. Isogai, “Relationship between urinary excretion of fibronectin degradation products and proteinuria in diabetic patients, and their suppression after continuous subcutaneous heparin infusion,” Diabetes Research and Clinical Practice, vol. 21, no. 1, pp. 61–66, 1993. View at Publisher · View at Google Scholar · View at Scopus
  46. A. L. Al-Malki, “Assessment of urinary osteopontin in association with podocyte for early predication of nephropathy in diabetic patients,” Disease Markers, vol. 2014, Article ID 493736, 5 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Mise, J. Hoshino, T. Ueno et al., “Prognostic value of tubulointerstitial lesions, urinary N-acetyl-β-d-glucosaminidase, and urinary β2-microglobulin in patients with type 2 diabetes and biopsy-proven diabetic nephropathy,” Clinical Journal of the American Society of Nephrology, vol. 11, no. 4, pp. 593–601, 2016. View at Publisher · View at Google Scholar
  48. K. M. Schmidt-Ott, K. Mori, Y. L. Jau et al., “Dual action of neutrophil gelatinase-associated lipocalin,” Journal of the American Society of Nephrology, vol. 18, no. 2, pp. 407–413, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Bolignano, A. Lacquaniti, G. Coppolino et al., “Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients,” Kidney & Blood Pressure Research, vol. 32, no. 2, pp. 91–98, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. Z. Yürük Yıldırım, A. Nayır, A. Yılmaz, A. Gedikbaşı, and R. Bundak, “Neutrophil gelatinase-associated lipocalin as an early sign of diabetic kidney injury in children,” Journal of Clinical Research in Pediatric Endocrinology, vol. 7, no. 4, pp. 274–279, 2015. View at Publisher · View at Google Scholar
  51. A. Lacquaniti, V. Donato, B. Pintaudi et al., “‘Normoalbuminuric’ diabetic nephropathy: tubular damage and NGAL,” Acta Diabetologica, vol. 50, no. 6, pp. 935–942, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. J. A. de Carvalho, E. Tatsch, B. S. Hausen et al., “Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular damage in normoalbuminuric patients with type 2 diabetes,” Clinical Biochemistry, vol. 49, no. 3, pp. 232–236, 2016. View at Publisher · View at Google Scholar
  53. W.-J. Fu, S.-L. Xiong, Y.-G. Fang et al., “Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study,” Endocrine, vol. 41, no. 1, pp. 82–88, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. V. Garg, M. Kumar, H. S. Mahapatra, A. Chitkara, A. K. Gadpayle, and V. Sekhar, “Novel urinary biomarkers in pre-diabetic nephropathy,” Clinical and Experimental Nephrology, vol. 19, no. 5, pp. 895–900, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. Y.-H. Yang, X.-J. He, S.-R. Chen, L. Wang, E.-M. Li, and L.-Y. Xu, “Changes of serum and urine neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy: one year observational follow-up study,” Endocrine, vol. 36, no. 1, pp. 45–51, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. M. H. Weber and R. Verwiebe, “α1- microglobulin (protein HC): features of a promising indicator of proximal tubular dysfunction,” European Journal of Clinical Chemistry and Clinical Biochemistry, vol. 30, no. 10, pp. 683–691, 1992. View at Google Scholar · View at Scopus
  57. C.-Y. Hong, K. Hughes, K.-S. Chia, V. Ng, and S.-L. Ling, “Urinary α1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore,” Diabetes Care, vol. 26, no. 2, pp. 338–342, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. L. Petrica, M. Petrica, A. Vlad et al., “Proximal tubule dysfunction is dissociated from endothelial dysfunction in normoalbuminuric patients with type 2 diabetes mellitus: a cross-sectional study,” Nephron Clinical Practice, vol. 118, no. 2, pp. c155–c164, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Wainai, F. Katsukawa, I. Takei, H. Maruyama, K. Kataoka, and T. Saruta, “Influence of glycemic control and hypertension on urinary microprotein excretion in non-insulin-dependent diabetes mellitus,” Journal of Diabetic Complications, vol. 5, no. 2-3, pp. 160–161, 1991. View at Publisher · View at Google Scholar · View at Scopus
  60. N. Shore, R. Khurshid, and M. Saleem, “Alpha-1 microglobulin: a marker for early detection of tubular disorders in diabetic nephropathy,” Journal of Ayub Medical College, Abbottabad, vol. 22, no. 4, pp. 53–55, 2010. View at Google Scholar · View at Scopus
  61. J. V. Bonventre, “Kidney injury molecule-1: a translational journey,” Transactions of the American Clinical and Climatological Association, vol. 125, pp. 293–299, 2014. View at Google Scholar
  62. L. Petrica, A. Vlad, G. Gluhovschi et al., “Proximal tubule dysfunction is associated with podocyte damage biomarkers nephrin and vascular endothelial growth factor in type 2 diabetes mellitus patients: a cross-sectional study,” PLoS ONE, vol. 9, no. 11, Article ID e112538, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. S. E. Nielsen, K. J. Schjoedt, A. S. Astrup et al., “Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril,” Diabetic Medicine, vol. 27, no. 10, pp. 1144–1150, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. S. E. Nielsen, H. Reinhard, D. Zdunek et al., “Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients,” Diabetes Research and Clinical Practice, vol. 97, no. 1, pp. 71–76, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. C. Bazzi, C. Petrini, V. Rizza et al., “Urinary N-acetyl-β-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis,” Nephrology Dialysis Transplantation, vol. 17, no. 11, pp. 1890–1896, 2002. View at Publisher · View at Google Scholar · View at Scopus
  66. A. P. Jones, S. Lock, and K. D. Griffiths, “Urinary N-acetyl-β-glucosaminidase activity in type I diabetes mellitus,” Annals of Clinical Biochemistry, vol. 32, no. 1, pp. 58–62, 1995. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Uslu, B. Efe, Ö. Alataş et al., “Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients,” Journal of Nephrology, vol. 18, no. 5, pp. 559–567, 2005. View at Google Scholar · View at Scopus
  68. V. Ambade, P. Singh, B. L. Somani, and D. Basannar, “Urinary N-acetyl beta glucosaminidase and gamma glutamyl transferase as early markers of diabetic nephropathy,” Indian Journal of Clinical Biochemistry, vol. 21, no. 2, pp. 142–148, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. D. N. Patel and K. Kalia, “Efficacy of urinary N-acetyl-β-d-glucosaminidase to evaluate early renal tubular damage as a consequence of type 2 diabetes mellitus: a cross-sectional study,” International Journal of Diabetes in Developing Countries, vol. 35, supplement 3, pp. 449–457, 2015. View at Publisher · View at Google Scholar
  70. H. S. Assal, S. Tawfeek, E. A. Rasheld, D. El-Lebedy, and E. H. Thabet, “Serum cystatin C and tubular urinary enzymes as biomarkers: a renal dysfunction in type 2 diabetes mellitus,” Clinical Medicine Insights: Endocrinology and Diabetes, vol. 6, no. 7, pp. 7–13, 2013. View at Google Scholar
  71. M. Kamiyama, A. Zsombok, and H. Kobori, “Urinary angiotensinogen as a novel early biomarker of intrarenal renin-angiotensin system activation in experimental type 1 diabetes,” Journal of Pharmacological Sciences, vol. 119, no. 4, pp. 314–323, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. T. Saito, M. Urushihara, Y. Kotani, S. Kagami, and H. Kobori, “Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes,” American Journal of the Medical Sciences, vol. 338, no. 6, pp. 478–480, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. Z. Zhuang, Q. Bai, L. A, T. Liang, D. Zheng, and Y. Wang, “Increased urinary angiotensinogen precedes the onset of albuminuria in normotensive type 2 diabetic patients,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 9, pp. 11464–11469, 2015. View at Google Scholar
  74. S. S. Kim, S. H. Song, I. J. Kim et al., “Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients,” Diabetes Research and Clinical Practice, vol. 97, no. 2, pp. 251–257, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Sawaguchi, S.-I. Araki, H. Kobori et al., “Association between urinary angiotensinogen levels and renal and cardiovascular prognoses in patients with type 2 diabetes mellitus,” Journal of Diabetes Investigation, vol. 3, no. 3, pp. 318–324, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. T. Mizushige, H. Kobori, Y. Nishijima et al., “Urinary angiotensinogen could be a prognostic marker of renoprotective effects of alogliptin in patients with type 2 diabetes,” Journal of Diabetes Research, vol. 2015, Article ID 517472, 7 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  77. Y. K. Jeon, M. R. Kim, J. E. Huh et al., “Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes,” Journal of Korean Medical Science, vol. 26, no. 2, pp. 258–263, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. W. D. Comper, T. M. Osicka, and G. Jerums, “High prevalence of immuno-unreactive intact albumin in urine of diabetic patients,” American Journal of Kidney Diseases, vol. 41, no. 2, pp. 336–342, 2003. View at Publisher · View at Google Scholar · View at Scopus
  79. X. Rao, M. Wan, C. Qiu, and C. Jiang, “Role of cystatin C in renal damage and the optimum cut-off point of renal damage among patients with type 2 diabetes mellitus,” Experimental and Therapeutic Medicine, vol. 8, no. 3, pp. 887–892, 2014. View at Publisher · View at Google Scholar · View at Scopus
  80. V. Garg, M. Kuman, H. S. Mahapatra, A. Chitkora, A. K. Gadpoyle, and V. Sekhan, “Novel urinary biomarkers in prediabetic nephropathy,” Clinical and Experimental Nephrology, vol. 19, no. 5, pp. 895–890, 2015. View at Publisher · View at Google Scholar
  81. S. S. Kim, S. H. Song, I. J. Kim et al., “Urinary cystatin C and tubular proteinuria predict progression of diabetic nephropathy,” Diabetes Care, vol. 36, no. 3, pp. 656–661, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. A. Kamijo-Ikemori, T. Sugaya, T. Yasuda et al., “Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients,” Diabetes Care, vol. 34, no. 3, pp. 691–696, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. S. E. Nielsen, T. Sugaya, P. Hovind, T. Baba, H.-H. Parving, and P. Rossing, “Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients,” Diabetes Care, vol. 33, no. 6, pp. 1320–1324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. V. Viswanathan, S. Sivakumar, V. Sekar, D. M. Umapathy, and S. Kumpatla, “Clinical significance of urinary liver-type fatty acid binding protein at various stages of nephropathy,” Indian Journal of Nephrology, vol. 25, no. 5, pp. 269–273, 2015. View at Publisher · View at Google Scholar · View at Scopus
  85. K.-M. Chou, C.-C. Lee, C.-H. Chen, and C.-Y. Sun, “Clinical value of NGAL, L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients,” PLoS ONE, vol. 8, no. 1, article e54863, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. N. M. Panduru, C. Forsblom, M. Saraheimo et al., “Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes,” Diabetes Care, vol. 36, no. 7, pp. 2077–2083, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. G. I. Welsh and M. A. Saleem, “Nephrin—signature molecule of the glomerular podocyte?” The Journal of Pathology, vol. 220, no. 3, pp. 328–337, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. F. N. Ziyadeh and G. Wolf, “Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy,” Current Diabetes Reviews, vol. 4, no. 1, pp. 39–45, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Pätäri, C. Forsblom, M. Havana, H. Taipale, P.-H. Groop, and H. Holthöfer, “Nephrinuria in diabetic nephropathy of type 1 diabetes,” Diabetes, vol. 52, no. 12, pp. 2969–2974, 2003. View at Publisher · View at Google Scholar · View at Scopus
  90. D. P. K. Ng, B.-C. Tai, E. Tan et al., “Nephrinuria associates with multiple renal traits in type 2 diabetes,” Nephrology Dialysis Transplantation, vol. 26, no. 8, pp. 2508–2514, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. Y. Kandasamy, R. Smith, E. R. Lumbers, and D. Rudd, “Nephrin a biomarker of early glomerular injury,” Biomarker Research, vol. 2, no. 1, p. 21, 2014. View at Publisher · View at Google Scholar
  92. B. Jim, M. Ghanta, A. Qipo et al., “Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: a cross sectional study,” PLoS ONE, vol. 7, no. 5, Article ID e36041, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. J. F. Navarro, C. Mora, M. Gómez, M. Muros, C. López-Aguilar, and J. García, “Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-α and interleukin-6 in type 2 diabetic patients,” Nephrology Dialysis Transplantation, vol. 23, no. 3, pp. 919–926, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. D. Z. I. Cherney, J. W. Scholey, D. Daneman et al., “Urinary markers of renal inflammation in adolescents with type 1 diabetes mellitus and normoalbuminuria,” Diabetic Medicine, vol. 29, no. 10, pp. 1297–1302, 2012. View at Publisher · View at Google Scholar · View at Scopus
  95. R. Har, J. W. Scholey, D. Daneman et al., “The effect of renal hyperfiltration on urinary inflammatory cytokines/chemokines in patients with uncomplicated type 1 diabetes mellitus,” Diabetologia, vol. 56, no. 5, pp. 1166–1173, 2013. View at Publisher · View at Google Scholar · View at Scopus
  96. K. Tashiro, I. Koyanagi, A. Saitoh et al., “Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy,” Journal of Clinical Laboratory Analysis, vol. 16, no. 1, pp. 1–4, 2002. View at Publisher · View at Google Scholar
  97. J. Liu, Z. Zhao, M. D. P. Willcox, B. Xu, and B. Shi, “Multiplex bead analysis of urinary cytokines of type 2 diabetic patients with normo- and microalbuminuria,” Journal of Immunoassay and Immunochemistry, vol. 31, no. 4, pp. 279–289, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. S. Ibrahim and L. Rashed, “Correlation of urinary monocyte chemo-attractant protein-1 with other parameters of renal injury in type-II diabetes mellitus,” Saudi Journal of Kidney Diseases and Transplantation, vol. 19, no. 6, pp. 911–917, 2008. View at Google Scholar · View at Scopus
  99. H. Jiang, G. Guan, R. Zhang et al., “Increased urinary excretion of orosomucoid is a risk predictor of diabetic nephropathy,” Nephrology, vol. 14, no. 3, pp. 332–337, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. N. M. El-Beblawy, N. G. Andrawes, E. A. Ismail, B. E. Enany, H. S. Abou El-Seoud, and M. A. Erfan, “Serum and Urinary orosomucoid in young patients with type 1 diabetes: a link between inflammation, microvascular complications, and subclinical atherosclerosis,” Clinical and Applied Thrombosis/Hemostasis, 2016. View at Publisher · View at Google Scholar
  101. M. S. Christiansen, E. Hommel, E. Magid, and B. Feldt-Rasmussen, “Orosomucoid in urine predicts cardiovascular and over-all mortality in patients with type II diabetes,” Diabetologia, vol. 45, no. 1, pp. 115–120, 2002. View at Publisher · View at Google Scholar · View at Scopus
  102. H. Ha and H. B. Lee, “Oxidative stress in diabetic nephropathy: basic and clinical information,” Current Diabetes Reports, vol. 1, no. 3, pp. 282–287, 2001. View at Publisher · View at Google Scholar · View at Scopus
  103. L. L. Wu, C. C. Chiou, P. Y. Chang, and J. T. Wu, “Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics,” Clinica Chemica Acta, vol. 339, no. 1-2, pp. 1–9, 2004. View at Google Scholar
  104. Y. Hinokio, S. Suzuki, M. Hirai, C. Suzuki, M. Suzuki, and T. Toyota, “Urinary excretion of 8-oxo-7, 8-dihydro-2′-deoxyguanosine as a predictor of the development of diabetic nephropathy,” Diabetologia, vol. 45, no. 6, pp. 877–882, 2002. View at Publisher · View at Google Scholar · View at Scopus
  105. J. Leinonen, T. Lehtimäki, S. Toyokuni et al., “New biomarker evidence of oxidative DNA damage in patients with non-insulin-dependent diabetes mellitus,” FEBS Letters, vol. 417, no. 1, pp. 150–152, 1997. View at Publisher · View at Google Scholar · View at Scopus
  106. K. Broedbaek, A. Weimann, E. S. Stovgaard, and H. E. Poulsen, “Urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine as a biomarker in type 2 diabetes,” Free Radical Biology and Medicine, vol. 51, no. 8, pp. 1473–1479, 2011. View at Publisher · View at Google Scholar · View at Scopus
  107. F. L. Nauta, W. E. Boertien, S. J. L. Bakker et al., “Glomerular and tubular damage markers are elevated in patients with diabetes,” Diabetes Care, vol. 34, no. 4, pp. 975–981, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. L. Petrica, A. Vlad, G. Gluhovschi et al., “Glycated peptides are associated with proximal tubule dysfunction in type 2 diabetes mellitus,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 2, pp. 2516–2525, 2015. View at Google Scholar · View at Scopus
  109. N. Turk, A. Mornar, V. Mrzljak, and Z. Turk, “Urinary excretion of advanced glycation endproducts in patients with type 2 diabetes and various stages of proteinuria,” Diabetes and Metabolism, vol. 30, no. 2, pp. 187–192, 2004. View at Publisher · View at Google Scholar · View at Scopus
  110. A. A. Ghanem, A. Elewa, and L. F. Arafa, “Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy,” European Journal of Ophthalmology, vol. 21, no. 1, pp. 48–54, 2011. View at Publisher · View at Google Scholar · View at Scopus
  111. F. Piarulli, G. Sartore, A. Ceriello et al., “Relationship between glyco-oxidation, antioxidant status and microalbuminuria in type 2 diabetic patients,” Diabetologia, vol. 52, no. 7, pp. 1419–1425, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. M. Shoji, K. Kobayashi, M. Takemoto, Y. Sato, and K. Yokote, “Urinary podocalyxin levels were associated with urinary albumin levels among patients with diabetes,” Biomarkers, vol. 21, no. 2, pp. 164–167, 2015. View at Publisher · View at Google Scholar
  113. M. Hara, K. Yamagata, Y. Tomino et al., “Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin,” Diabetologia, vol. 55, no. 11, pp. 2913–2919, 2012. View at Publisher · View at Google Scholar · View at Scopus
  114. M. Zheng, L.-L. Lv, J. Ni et al., “Urinary podocyte-associated mRNA profile in various stages of diabetic nephropathy,” PLoS ONE, vol. 6, no. 5, Article ID e20431, 2011. View at Publisher · View at Google Scholar · View at Scopus
  115. N. H. Kim, K. B. Kim, D. L. Kim et al., “Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in type 2 diabetes mellitus,” Diabetic Medicine, vol. 21, no. 6, pp. 545–551, 2004. View at Publisher · View at Google Scholar · View at Scopus
  116. M. Emoto, K. Mori, E. Lee et al., “Fetuin-A and atherosclerotic calcified plaque in patients with type 2 diabetes mellitus,” Metabolism: Clinical and Experimental, vol. 59, no. 6, pp. 873–878, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. K. Inoue, J. Wada, J. Eguchi et al., “Urinary fetuin-A is a novel marker for diabetic nephropathy in type 2 diabetes identified by lectin microarray,” PLoS ONE, vol. 8, no. 10, Article ID e77118, 2013. View at Publisher · View at Google Scholar · View at Scopus
  118. M. A. K. Salem, S. A. El-Habashy, O. M. Saeid, M. M. K. El-Tawil, and P. H. Tawfik, “Urinary excretion of N-acetyl-β-d-glucosaminidase and retinol binding protein as alternative indicators of nephropathy in patients with type 1 diabetes mellitus,” Pediatric Diabetes, vol. 3, no. 1, pp. 37–41, 2002. View at Publisher · View at Google Scholar · View at Scopus
  119. V. Lambadiari, N. P. E. Kadoglou, V. Stasinos et al., “Serum levels of retinol-binding protein-4 are associated with the presence and severity of coronary artery disease,” Cardiovascular Diabetology, vol. 13, no. 1, article 121, 2014. View at Publisher · View at Google Scholar · View at Scopus
  120. A. Shoukry, S. E.-A. Bdeer, and R. H. El-Sokkary, “Urinary monocyte chemoattractant protein-1 and vitamin D-binding protein as biomarkers for early detection of diabetic nephropathy in type 2 diabetes mellitus,” Molecular and Cellular Biochemistry, vol. 408, no. 1, pp. 25–35, 2015. View at Publisher · View at Google Scholar · View at Scopus
  121. Z. Li, Y. Xu, Y. Nie, and Z. Zhao, “Urinary heme oxygenase-1 as a potential biomarker for early diabetic nephropathy,” Nephrology (Carlton, Vic.), 2016. View at Publisher · View at Google Scholar
  122. B. Satirapoj, S. Tassanasorn, M. Charoenpitakchai, and O. Supasyndh, “Periostin as a tissue and urinary biomarker of renal injury in type 2 diabetes mellitus,” PLoS ONE, vol. 10, no. 4, Article ID e0124055, 2015. View at Publisher · View at Google Scholar · View at Scopus
  123. E. Y. Lee, S. S. Kim, J.-S. Lee et al., “Soluble α-klotho as a novel biomarker in the early stage of nephropathy in patients with type 2 diabetes,” PLoS ONE, vol. 9, no. 8, article e102984, 2014. View at Publisher · View at Google Scholar · View at Scopus
  124. A.-L. Sun, J.-T. Deng, G.-J. Guan et al., “Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease,” Diabetes and Vascular Disease Research, vol. 9, no. 4, pp. 301–308, 2012. View at Publisher · View at Google Scholar · View at Scopus
  125. Y. Yang, L. Xiao, J. Li, Y. S. Kanwar, F. Liu, and L. Sun, “Urine miRNAs: potential biomarkers for monitoring progression of early stages of diabetic nephropathy,” Medical Hypotheses, vol. 81, no. 2, pp. 274–278, 2013. View at Publisher · View at Google Scholar · View at Scopus
  126. C. Argyropoulos, K. Wang, J. Bernardo et al., “Urinary MicroRNA profiling predicts the development of microalbuminuria in patients with type 1 Diabetes,” Journal of Clinical Medicine, vol. 4, no. 7, pp. 1495–1517, 2015. View at Publisher · View at Google Scholar
  127. M. W. Kennedy, A. P. Heikema, A. Cooper, P. J. Bjorkman, and L. M. Sanchez, “Hydrophobic ligand binding by Zn-α2-glycoprotein, a soluble fat-depleting factor related to major histocompatibility complex proteins,” Journal of Biological Chemistry, vol. 276, no. 37, pp. 35008–35013, 2001. View at Publisher · View at Google Scholar · View at Scopus
  128. Y. Wang, Y. M. Li, S. Zhang, J. Y. Zhao, and C. Y. Liu, “Adipokine zinc-α-2- glycoprotein as novel urinary biomarker presents early than microalbuminuria in diabetic nephropathy,” Journal of International Medical Research, vol. 44, no. 2, pp. 278–286, 2016. View at Publisher · View at Google Scholar
  129. S. C. Lim, D. Q. Liying, W. C. Toy et al., “Adipocytokine zinc α2 glycoprotein (ZAG) as a novel urinary biomarker for normo-albuminuric diabetic nephropathy,” Diabetic Medicine, vol. 29, no. 7, pp. 945–949, 2012. View at Publisher · View at Google Scholar · View at Scopus
  130. V. Thongboonkerd, “Study of diabetic nephropathy in the proteomic era,” Diabetes and the Kidney, vol. 170, pp. 172–183, 2011. View at Publisher · View at Google Scholar · View at Scopus
  131. K. N. Lai and S. C. W. Tang, Eds., Diabetes and the Kidney, vol. 170, Contributions to Nephrology, Karger, Basel, Switzerland, 2011.
  132. P. Zürbig, G. Jerums, P. Hovind et al., “Urinary proteomics for early diagnosis in diabetic nephropathy,” Diabetes, vol. 61, no. 12, pp. 3304–3313, 2012. View at Publisher · View at Google Scholar · View at Scopus
  133. F. Raimondo, S. Corbetta, L. Morosi et al., “Urinary exosomes and diabetic nephropathy: a proteomic approach,” Molecular BioSystems, vol. 9, no. 6, pp. 1139–1146, 2013. View at Publisher · View at Google Scholar · View at Scopus
  134. I. Zubiri, M. Posada-Ayala, A. Sanz-Maroto et al., “Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis,” Journal of Proteomics, vol. 96, pp. 92–102, 2014. View at Publisher · View at Google Scholar · View at Scopus
  135. A. Caseiro, A. Barros, R. Ferreira et al., “Pursuing type 1 diabetes mellitus and related complications through urinary proteomics,” Translational Research, vol. 163, no. 3, pp. 188–199, 2014. View at Publisher · View at Google Scholar · View at Scopus
  136. B. Jim, J. Santos, F. Spath, and J. C. He, “Biomarkers of diabetic nephropathy, the present and the future,” Current Diabetes Reviews, vol. 8, no. 5, pp. 317–328, 2012. View at Publisher · View at Google Scholar · View at Scopus